Drugs / Fluarix Tetra
Fluarix Tetra
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT05734040 | May → Aug 2023 | influenza | Osivax | Completed | No outcome recorded |
| Phase 2 | NCT05284799 | May → Jul 2022 | influenza | Osivax | Completed | No outcome recorded |
| Phase 2 | NCT05082688 | Sep 2021 → May 2023 | herpes zoster, influenza | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02369341 | Apr → Jun 2015 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT06824779 | Dec 2025 overdue | — | University Hospital of Saint-Etienne | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05648357 | Dec 2023 → Feb 2024 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05315024 | Apr 2022 → Sep 2023 | influenza | The University of Hong Kong | Unknown | No outcome recorded |
| — | NCT02557802 | Oct 2015 → Jan 2016 | influenza | University of Surrey | Completed | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04381689 Comparator | Oct 2024 → May 2025 | — | Il-Yang Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT06602024 Comparator | Sep 2024 → Aug 2025 | influenza | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05415462 Comparator | Jun 2022 → Sep 2023 | influenza | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03718468 Comparator | Oct 2018 → Jul 2019 | influenza | Medigen Vaccine Biologics Corp. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluarix Tetra | “Flu vaccination by one of FLU vaccines in the french market : FluarixTetra® (GSK), VaxigripTetra® (Sanofi-Pasteur), Influvac Tetra® (VIATRIS MEDICAL)” NCT06824779 ↗12“Subjects aged 18-60 years received 1 dose of Fluarix™ Tetra (Southern Hemisphere) vaccine at Day 0.” NCT02369341 ↗ |
| Known as | FLU D-QIV (GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra) | “FLU D-QIV (GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra)” NCT02369341 ↗ |
| Modality | Vaccine | “Quadrivalent Split Virion Influenza Vaccine” NCT02369341 ↗ |
| Route | Intramuscular | “intramuscularly into the deltoid of the non-dominant arm.” NCT02369341 ↗ |